

Epidemiologic/Correlative

- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)
- UCI 14-36** A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay
- UCI 16-01** Pathway Analysis for Individualized Network Therapeutic for Cancer (PAINT) (Nelson)
- UCI 16-43** Prospective Collection of Human Colon Cancer Tissue Samples for Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers (Lyou)
- UCI 15-20** A Pilot Study to Establish Proof-of-Concept that Patient-Specific Tumor Tissue can be Maintained in the Novel Tumor-on-a-Chip Model (Zell)

Therapeutic - Multi-site (including colon)

- UCI 14-39** Phase I/Ib, Two-Part, Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study of DS-6051B, An Oral ROS1 And NTRK Inhibitor, In Subjects With Advanced Solid Tumors (Ou)
- UCI 15-74** Phase II Entrectinib Tx Patients with Locally Advanced/Metastatic Solid Tumors Harbor NTRK1/2/3, ROS1, ALK Gene (Seery)

COLORECTAL CANCER

Screening

- UCI 12-40** Atlas Colorectal Health Network (Park)
- UCI 14-30** Low Residue Diet vs. Clear Liquid Diet w/ Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy (Samarasena)

**Stage IIA/IIIA
(T2N1,T3N0,T3N1)**

Neoadjuvant

SWOG N1048 Phase II/III Trial of Neoadjuvant FOLFOX w/
Selective Use of Combined Modality Chemoradiation VS
Preoperative Combined Modality Chemoradiation for Locally
Advanced Rectal CA Pts Undergoing LAR W/Total Mesorectal
Excision (Pigazzi)

Post-Adjuvant

Stage 0-III

SWOG S0820 Phase IIA Randomized
Double Blind Placebo-Controlled Trial of
Eflornithine and Sulindac to Prevent
Recurrence of High-Risk Adenomas and
Second Primary Colorectal Cancers in
Patients with Stage 0-III Colon Cancer
(Zell)

**COLORECTAL
CANCER**

Perioperative

UCI 17-28** Immediate Adjuvant
Chemotherapy for Invasive Colonic
Adenocarcinoma (Pigazzi)

Stage IV

1st Line

UCI 15-96 A Phase III Study of
Pembrolizumab (MK-3475) vs.
Chemotherapy in Microsatellite Instability-
High (MSI-H) or Mismatch Repair Deficient
(dMMR) Stage IV Colorectal Carcinoma
(Zell)

2nd Line

SWOG E7208 A Randomized Phase II
Study of Irinotecan and Cetuximab with
or without the Anti-Angiogenic Antibody,
Ramucirumab (IMC-1121B), in Advanced,
K-ras Wild-type Colorectal Cancer
Following Progression on Bevacizumab-
Containing Chemotherapy (Zell)

ECOG-EAY131 Molecular Analysis for
Therapy Choice (MATCH)
(Seery)